More and more countries are completing their epidemiological mapping of trachoma in suspected endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of “trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass drug administration (MDA) is normally at the district level and targets the whole population with Zithromax® tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5 years of age; and tetracycline eye ointment 1% for infants up to 6 months old.